L-Tyrosine for ADHD and Depression

by | Aug 5, 2008

Description

L-Tyrosine is an important amino acid (protein building block) that the body makes from another amino acid known as L-Phenylalanine. L-Tyrosine is included in almost all structural proteins in the body. It is also the precursor of several neurotransmitters, including L-Dopa, Dopamine, Norepinephrine, and Epinephrine. L-Tyrosine deficiencies may be associated with several health conditions, including Parkinson’s disease, depression, ADD and other mood disorders.


Additionally, L-Tyrosine is converted by skin cells into melanin, the skin pigment that protects against the harmful effects of ultraviolet light. L-Tyrosine is also an integral component of Thyroid hormones, which play an important role in almost every process of the body. Tyrosine supplementation may be beneficial in some people with Phenylketonuria (PKU), though the evidence is conflicting.(10) People born with this genetic condition are unable to process and use L-Phenylalanine. Mental retardation and other severe disabilities can result. While dietary L-Phenylalanine restriction prevents these problems, it also leads to low tyrosine levels in many (but not all) people with PKU.

Dose

Most experts recommend L-Tyrosine supplementation in the range of 500 – 1500 mg, 2-3 times daily for periods of 3-12 months. L-Tyrosine may need to be supplemented with its synergistic amino acids including L-Phenylalanine, L-Methionine, and 5-Hydroxytryptophan. Additionally, Vitamin B6, B12, C and Folic acid are necessary for conversion of L-Tyrosine into neurotransmitters. The appropriate amount to use depends on the symptoms and specific health problem of the individual, therefore, the monitoring of blood, and/or saliva levels by a physician is recommended.

Research

Studies have suggested that tyrosine may help people with depression.(1) A deficiency of the Neurohormones Epinephrine (Epi) and Norepinephrine (NE) is associated with Attention Deficit Disorder (ADD). Low levels of Epi and NE are associated with mental dullness, poor concentration and apathy. High levels of both cause hyperactivity and anxiety. Low levels of Epi and high levels of NE cause hyperactivity and poor concentration.

Preliminary findings indicate a beneficial effect of tyrosine, along with other amino acids, in people affected by dementia, including Alzheimer’s disease.(2) Due to its role as a precursor to Norepinephrine and epinephrine (two of the body’s main stress-related hormones) tyrosine may also ease the adverse effects of environmental, psychosocial, and physical stress. (3 4 5 6 7 8 9)

Adverse Effects

L-Tyrosine has not been reported to cause any serious side effects.

References

1.

Gelenberg AJ, Gibson CJ, Wojcik JD. Neurotransmitter precursors for the treatment of depression. Psychopharmacol Bull 1982;18:7–18.

2.

Meyer JS, Welch KMA, Deshmuckh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer’s disease. J Am Geriatr Soc 1977;7:289–98.

3.

Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull 1989;22:759–62.

4.

Salter CA. Dietary tyrosine as an aid to stress resistance among troops. Mil Med 1989;154:144–6.

5.

Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosine on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995;66:313–9.

6.

Deijen JB, Wientjes CJ, Vullinghs HF, et al. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Res Bull 1999;48:203–9.

7.

Shurtleff D, Thomas JR, Schrot J, et al. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav 1994;47:935–41.

8.

Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull 1994;33:319–23.

9.

Dollins AB, Krock LP, Storm WF, et al. L-tyrosine ameliorates some effects of lower body negative pressure stress. Physiol Behav 1995;57:223–30.

10.

Koch R. Tyrosine supplementation for phenylketonuria treatment. Am J Clin Nutr 1996;64:974–5.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

2 + 11 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });